The thrombopoietin receptor: revisiting the master regulator of platelet production

Autor(en): Hitchcock, Ian S.
Hafer, Maximillian
Sangkhae, Veena
Tucker, Julie A.
Stichwörter: ACTIVATION; C-MPL MUTATIONS; Cell Biology; GENE; GLYCAN DOMAIN; Hematology; HEPATIC THROMBOPOIETIN; HEREDITARY THROMBOCYTHEMIA; IDENTIFICATION; MEGAKARYOCYTE GROWTH; megakaryocytes; platelets; signaling; SPLICE DONOR MUTATION; THROMBOCYTOPENIA; Thrombopoietin; thrombopoietin receptor
Erscheinungsdatum: 2021
Herausgeber: TAYLOR & FRANCIS INC
Journal: PLATELETS
Volumen: 32
Ausgabe: 6
Startseite: 770
Seitenende: 778
Zusammenfassung: 
Thrombopoietin (TPO) and its receptor, MPL, are the primary regulators of platelet production and critical for hematopoietic stem cell (HSC) maintenance. Since TPO was first cloned in 1994, the physiological and pathological roles of TPO and MPL have been well characterized, culminating in the first MPL agonists being approved for the treatment of chronic immune thrombocytopenia in 2008. Dysregulation of the TPO-MPL signaling axis contributes to the pathogenesis of hematological disorders: decreased expression or function results in severe thrombocytopenia progressing to bone marrow failure, while hyperactivation of MPL signaling, either by mutations in the receptor or associated Janus kinase 2 (JAK2), results in pathological myeloproliferation. Despite its importance, it was only recently that the long-running debate over the mechanism by which TPO binding activates MPL has been resolved. This review will cover key aspects of TPO and MPL structure and function and their importance in receptor activation, discuss how these are altered in hematological disorders and consider how a greater understanding could lead to the development of better-targeted and more efficacious therapies.
ISSN: 09537104
DOI: 10.1080/09537104.2021.1925102

Show full item record

Google ScholarTM

Check

Altmetric